ADVERTISEMENTs
Trump’s 100% pharma tariffs cloud India–US trade talks, expose fragility of partnership
President Donald Trump announced on Sept. 25 a 100 percent tariff on branded and patented pharmaceutical imports, effective Oct. 1, 2025, unless companies establish manufacturing facilities in the United States.
-
R Suryamurthy - Fri, 26, Sep 2025
- 23:37 EDT
- 12
U.S. President Donald Trump reacts after signing a memorandum in the Oval Office at the White House in Washington, D.C., U.S., September 15, 2025. / REUTERS/Jonathan Ernst
Barely two days after India’s Commerce Minister Piyush Goyal returned from Washington following “constructive” trade talks, US President Donald Trump has announced 100 percent tariffs on imported branded and patented pharmaceuticals starting Oct. 1.
The move, pitched as part of his “America First” economic nationalism, puts India’s USD10 billion drug exports to the United States under renewed scrutiny and underscores the fragility of a trade relationship that both governments had only days ago described as moving toward a “mutually beneficial” agreement.
ALSO READ: Trump’s pharma tariff spares generics, but India still feels heat
This post is for paying subscribers only
SUBSCRIBE NOWRelated
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login